Key departures test EU regulatory network
This article was originally published in Scrip
News that the German regulator BfArM is seeking a new chair, while not a surprise in itself, will serve to fuel a sense of unease over developments in the wider European drug regulatory network.
You may also be interested in...
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.
The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.